2024 Q2 Form 10-Q Financial Statement

#000180116924000085 Filed on May 02, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $1.511B $1.181B
YoY Change -23.53% -62.15%
Cost Of Revenue $1.382B $1.067B
YoY Change -24.36% -63.83%
Gross Profit $129.0M $114.0M
YoY Change -13.42% -32.94%
Gross Profit Margin 8.54% 9.65%
Selling, General & Admin $164.0M $160.0M
YoY Change -2.38% -37.01%
% of Gross Profit 127.13% 140.35%
Research & Development $37.00M $41.00M
YoY Change -2.63% 2.5%
% of Gross Profit 28.68% 35.96%
Depreciation & Amortization $9.000M $9.000M
YoY Change -47.06% -10.0%
% of Gross Profit 6.98% 7.89%
Operating Expenses $201.0M $201.0M
YoY Change -2.43% -31.63%
Operating Profit -$72.00M -$87.00M
YoY Change 26.32% -29.84%
Interest Expense -$30.00M $37.00M
YoY Change -43.4% -50.0%
% of Operating Profit
Other Income/Expense, Net $12.00M $15.00M
YoY Change -70.73% -21.05%
Pretax Income -$91.00M -$109.0M
YoY Change -479.17% 7.92%
Income Tax $1.000M $200.0K
% Of Pretax Income
Net Earnings -$92.00M -$109.0M
YoY Change -500.0% 7.92%
Net Earnings / Revenue -6.09% -9.23%
Basic Earnings Per Share -$0.13 -$0.16
Diluted Earnings Per Share -$0.13 -$0.16
COMMON SHARES
Basic Shares Outstanding 691.6M shares 679.6M shares
Diluted Shares Outstanding 693.4M shares 682.5M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $809.0M $990.0M
YoY Change -33.14% -20.86%
Cash & Equivalents $790.0M $953.0M
Short-Term Investments $19.00M $37.00M
Other Short-Term Assets $61.00M $65.00M
YoY Change -96.46% 41.3%
Inventory $2.234B $1.881B
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.249B $3.284B
YoY Change -20.62% -33.95%
LONG-TERM ASSETS
Property, Plant & Equipment $71.00M $66.00M
YoY Change -21.11% 11.86%
Goodwill $4.000M $4.000M
YoY Change 0.0% 0.0%
Intangibles $2.000M $4.000M
YoY Change -77.78% -63.64%
Long-Term Investments
YoY Change
Other Assets $23.00M $23.00M
YoY Change -14.81% -14.81%
Total Long-Term Assets $123.0M $120.0M
YoY Change -5.38% -14.29%
TOTAL ASSETS
Total Short-Term Assets $3.249B $3.284B
Total Long-Term Assets $123.0M $120.0M
Total Assets $3.372B $3.404B
YoY Change -20.15% -33.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $73.00M $69.00M
YoY Change 12.31% -10.39%
Accrued Expenses $5.000M $5.000M
YoY Change -37.5% -54.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $315.0M
YoY Change 2000.0%
Total Short-Term Liabilities $393.0M $74.00M
YoY Change 346.59% -83.3%
LONG-TERM LIABILITIES
Long-Term Debt $2.116B $2.412B
YoY Change -30.12% -32.96%
Other Long-Term Liabilities $0.00 $1.000M
YoY Change -100.0% -97.14%
Total Long-Term Liabilities $0.00 $1.000M
YoY Change -100.0% -99.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $393.0M $74.00M
Total Long-Term Liabilities $0.00 $1.000M
Total Liabilities $2.527B $2.505B
YoY Change -19.45% -38.54%
SHAREHOLDERS EQUITY
Retained Earnings -$3.534B -$3.442B
YoY Change 12.69% 8.96%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $845.0M $899.0M
YoY Change
Total Liabilities & Shareholders Equity $3.372B $3.404B
YoY Change -20.15% -33.41%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$92.00M -$109.0M
YoY Change -500.0% 7.92%
Depreciation, Depletion And Amortization $9.000M $9.000M
YoY Change -47.06% -10.0%
Cash From Operating Activities -$399.0M -$178.0M
YoY Change -142.45% -108.23%
INVESTING ACTIVITIES
Capital Expenditures $8.000M $8.000M
YoY Change -11.11% 0.0%
Acquisitions
YoY Change
Other Investing Activities $17.00M $30.00M
YoY Change -29.17% -21.05%
Cash From Investing Activities $9.000M $22.00M
YoY Change -40.0% -26.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.00M -$98.00M
YoY Change -101.85% -92.6%
NET CHANGE
Cash From Operating Activities -399.0M -$178.0M
Cash From Investing Activities 9.000M $22.00M
Cash From Financing Activities 15.00M -$98.00M
Net Change In Cash -375.0M -$254.0M
YoY Change -356.85% -129.3%
FREE CASH FLOW
Cash From Operating Activities -$399.0M -$178.0M
Capital Expenditures $8.000M $8.000M
Free Cash Flow -$407.0M -$186.0M
YoY Change -143.72% -108.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2023Q1 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1000000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1000000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5000000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
74000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70000000 usd
CY2024Q1 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
2036000000 usd
CY2023Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
2134000000 usd
CY2024Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
376000000 usd
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
376000000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19000000 usd
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2505000000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2600000000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
688560794 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
677636163 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
688560794 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
677636163 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4341000000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4301000000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3442000000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3333000000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
899000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1086000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1000000 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
899000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
967000000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3404000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3567000000 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1181000000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3120000000 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
1067000000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
2950000000 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
114000000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
170000000 usd
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
113000000 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
188000000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47000000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66000000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41000000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40000000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
201000000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
294000000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-87000000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-124000000 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
78000000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
37000000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
74000000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101000000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-109000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101000000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
682457000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
641916000 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
682457000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
641916000 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-109000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-100000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
967000000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2000000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-109000000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
48000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1036000000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-109000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101000000 usd
CY2024Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
14000000 usd
CY2023Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
22000000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2000000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2000000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
33000000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
42000000 usd
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
7000000 usd
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
23000000 usd
CY2024Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-2000000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1000000 usd
CY2024Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
2000000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 usd
CY2024Q1 us-gaap Proceeds From Sale And Collection Of Loans Heldforsale
ProceedsFromSaleAndCollectionOfLoansHeldforsale
0 usd
CY2023Q1 us-gaap Proceeds From Sale And Collection Of Loans Heldforsale
ProceedsFromSaleAndCollectionOfLoansHeldforsale
1000000 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
78000000 usd
CY2024Q1 open Increase Decrease In Escrow Receivable
IncreaseDecreaseInEscrowReceivable
6000000 usd
CY2023Q1 open Increase Decrease In Escrow Receivable
IncreaseDecreaseInEscrowReceivable
12000000 usd
CY2024Q1 us-gaap Increase Decrease In Mortgage Loans Held For Sale
IncreaseDecreaseInMortgageLoansHeldForSale
114000000 usd
CY2023Q1 us-gaap Increase Decrease In Mortgage Loans Held For Sale
IncreaseDecreaseInMortgageLoansHeldForSale
-2306000000 usd
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
13000000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10000000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6000000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-22000000 usd
CY2024Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-8000000 usd
CY2024Q1 open Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2000000 usd
CY2023Q1 open Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-178000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2162000000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000000 usd
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30000000 usd
CY2024Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
CY2023Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
101000000 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000 usd
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2000000 usd
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1000000 usd
CY2024Q1 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 usd
CY2023Q1 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
224000000 usd
CY2024Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
100000000 usd
CY2023Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
1446000000 usd
CY2024Q1 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0 usd
CY2023Q1 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
4000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-98000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1325000000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-254000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
867000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1540000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1791000000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1286000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2658000000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
34000000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
74000000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5000000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
6000000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
953000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1143000000 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
333000000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1515000000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1286000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2658000000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that have a material impact on the amounts reported in the financial statements and accompanying notes. Significant estimates, assumptions and judgments made by management include, among others, the determination of the fair value of common stock, share-based awards, warrants, and inventory valuation adjustment. Management believes that the estimates and judgments upon which management relies are reasonable based upon information available to management at the time that these estimates and judgments are made. To the extent there are material differences between these estimates, assumptions and judgments and actual results, the carrying values of the Company's assets and liabilities and the results of operations will be affected. The health of the residential housing market and interest rate environment have introduced additional uncertainty with respect to judgments, estimates and assumptions, which may materially impact the estimates previously listed, among others.</span></div>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents, restricted cash, and investments in marketable securities. The Company places cash and cash equivalents and investments with major financial institutions, which management assesses to be of high credit quality, in order to limit exposure of the Company’s investments.</span></div>
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3000000 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2000000 usd
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3000000 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0 usd
CY2024Q1 us-gaap Inventory Adjustments
InventoryAdjustments
17000000 usd
CY2023Q4 us-gaap Inventory Adjustments
InventoryAdjustments
27000000 usd
CY2024Q1 us-gaap Inventory Real Estate Construction In Process
InventoryRealEstateConstructionInProcess
351000000 usd
CY2023Q4 us-gaap Inventory Real Estate Construction In Process
InventoryRealEstateConstructionInProcess
640000000 usd
CY2024Q1 us-gaap Inventory Real Estate Held For Sale
InventoryRealEstateHeldForSale
1024000000 usd
CY2023Q4 us-gaap Inventory Real Estate Held For Sale
InventoryRealEstateHeldForSale
882000000 usd
CY2024Q1 open Inventory Real Estate In Resale Contract
InventoryRealEstateInResaleContract
506000000 usd
CY2023Q4 open Inventory Real Estate In Resale Contract
InventoryRealEstateInResaleContract
253000000 usd
CY2024Q1 us-gaap Inventory Real Estate
InventoryRealEstate
1881000000 usd
CY2023Q4 us-gaap Inventory Real Estate
InventoryRealEstate
1775000000 usd
CY2024Q1 us-gaap Recorded Unconditional Purchase Obligation Minimum Quantity Required
RecordedUnconditionalPurchaseObligationMinimumQuantityRequired
2611 home
CY2024Q1 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
906000000 usd
CY2024Q1 open Inventory Real Estate Valuation Adjustment Decrease Increase
InventoryRealEstateValuationAdjustmentDecreaseIncrease
7000000 usd
CY2023Q1 open Inventory Real Estate Valuation Adjustment Decrease Increase
InventoryRealEstateValuationAdjustmentDecreaseIncrease
23000000 usd
CY2024Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
12000000 usd
CY2024Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
12000000 usd
CY2024Q1 open Equity Securities Fvni Cash And Cash Equivalents
EquitySecuritiesFVNICashAndCashEquivalents
0 usd
CY2024Q1 open Equity Securities Fvni Marketable Securities
EquitySecuritiesFVNIMarketableSecurities
12000000 usd
CY2024Q1 open Cash Cash Equivalents And Marketable Securities Amortized Cost
CashCashEquivalentsAndMarketableSecuritiesAmortizedCost
990000000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q1 open Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
990000000 usd
CY2024Q1 open Marketable Securities Cash And Cash Equivalents
MarketableSecuritiesCashAndCashEquivalents
953000000 usd
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
37000000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
15000000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
15000000 usd
CY2023Q4 open Equity Securities Fvni Cash And Cash Equivalents
EquitySecuritiesFVNICashAndCashEquivalents
0 usd
CY2023Q4 open Equity Securities Fvni Marketable Securities
EquitySecuritiesFVNIMarketableSecurities
15000000 usd
CY2023Q4 open Cash Cash Equivalents And Marketable Securities Amortized Cost
CashCashEquivalentsAndMarketableSecuritiesAmortizedCost
1069000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000000 usd
CY2023Q4 open Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
1068000000 usd
CY2023Q4 open Marketable Securities Cash And Cash Equivalents
MarketableSecuritiesCashAndCashEquivalents
999000000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
69000000 usd
CY2024Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-2000000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1000000 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
0 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
23000000 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
23000000 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
54000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
54000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000000 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
25000000 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
25000000 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 usd
CY2024Q1 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
20000000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
20000000 usd
CY2024Q1 us-gaap Equity Securities Fv Ni And Without Readily Determinable Fair Value
EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
20000000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni And Without Readily Determinable Fair Value
EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
20000000 usd
CY2024Q1 us-gaap Other Restricted Assets
OtherRestrictedAssets
263000000 usd
CY2023Q4 us-gaap Other Restricted Assets
OtherRestrictedAssets
275000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5000000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000 usd
CY2021Q3 open Option Indexed To Issuers Equity Cap Price Premium
OptionIndexedToIssuersEquityCapPricePremium
1
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
145000000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
166000000 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
79000000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100000000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66000000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66000000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000000 usd
CY2024Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 usd
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
29000000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25000000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
29000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24000000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33000000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
4000000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4000000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7820000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.44
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16000000 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
109000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.07
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.58
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7709000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.46
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7000000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7709000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.46
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y1M6D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7000000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000 usd
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0019
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0026
CY2023Q1 us-gaap Dividends
Dividends
0 usd
CY2024Q1 us-gaap Dividends
Dividends
0 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-109000000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-109000000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-101000000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-101000000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
682457000 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
682457000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
641916000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
641916000 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2024Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
66754000 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
89578000 shares
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
3000000 usd
CY2024Q1 us-gaap Restructuring Charges
RestructuringCharges
0 usd
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
3000000 usd
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
0 usd

Files In Submission

Name View Source Status
0001801169-24-000085-index-headers.html Edgar Link pending
0001801169-24-000085-index.html Edgar Link pending
0001801169-24-000085.txt Edgar Link pending
0001801169-24-000085-xbrl.zip Edgar Link pending
a101opendoortechnologiesin.htm Edgar Link pending
a102formofprsunoticeandagr.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
open-20240331.htm Edgar Link pending
open-20240331.xsd Edgar Link pending
open-20240331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
open-20240331_def.xml Edgar Link unprocessable
open-20240331_htm.xml Edgar Link completed
q12024exhibit311.htm Edgar Link pending
q12024exhibit312.htm Edgar Link pending
q12024exhibit321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
open-20240331_pre.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
open-20240331_lab.xml Edgar Link unprocessable